Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 1/2009

01-01-2009 | Original Research

Induced apoptosis with ultrasound-mediated microbubble destruction and shRNA targeting survivin in transplanted tumors

Authors: Zhi-Yi Chen, Kun Liang, Ming-Xing Xie, Xin-Fang Wang, Qing Lü, Jing Zhang

Published in: Advances in Therapy | Issue 1/2009

Login to get access
Metadata
Title
Induced apoptosis with ultrasound-mediated microbubble destruction and shRNA targeting survivin in transplanted tumors
Authors
Zhi-Yi Chen
Kun Liang
Ming-Xing Xie
Xin-Fang Wang
Qing Lü
Jing Zhang
Publication date
01-01-2009
Publisher
Springer Healthcare Communications
Published in
Advances in Therapy / Issue 1/2009
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-008-0129-4

Other articles of this Issue 1/2009

Advances in Therapy 1/2009 Go to the issue

Erratum

Sevikar®: Combination therapy for the treatment of hypertension

Original Research

Effects of loratadine/montelukast on vigilance and alertness task Performance in a simulated cabin environment

Review

Sevikar®: combination therapy for the treatment of hypertension

Review

Mecasermin (recombinant human insulin-like growth factor I)

Review

Ivabradine: Beyond heart rate control

Review

Temsirolimus in patients with advanced renal cell carcinoma: an overview
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits